Business Context and Reporting Period
Company: IDEAYA Biosciences, Inc. (IDYA)
Filing Type: Form 8-K (Current Report)
Date of Report: April 23, 2023
Subject: Item 8.01 Other Events – Clinical Updates regarding darovasertib and crizotinib in uveal melanoma.
Key Financial Metrics
This filing is a clinical update and does not contain financial statements. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Data
The Company announced interim results from Phase 2 trials and investigator-sponsored trials (IST) for darovasertib (with or without crizotinib) in metastatic uveal melanoma (MUM) and primary uveal melanoma (UM).
Phase 2: Darovasertib + Crizotinib in MUM
- First-Line Patients (n=20): 45% confirmed Overall Response Rate (ORR); 90% Disease Control Rate (DCR); ~7 months median Progression-Free Survival (PFS).
- Any-Line Patients (n=63): 30% confirmed ORR; 87% DCR; ~7 months median PFS. Median PFS improved from ~5 months reported in September 2022.
- Hepatic-Only MUM (n=20): 35% confirmed ORR; 100% DCR; ~11 months median PFS.
- Safety: Manageable profile; 31% reported Grade 3 adverse events (AEs); no Grade 4 AEs; one Grade 5 AE. 6% discontinued due to drug-related AEs.
(Neo)Adjuvant Primary UM
- Tumor Shrinkage: 100% of 9 evaluable patients (6 UM, 3 MUM) showed ocular tumor shrinkage.
- Case Study: One patient treated with darovasertib + crizotinib under compassionate use achieved ~80% tumor shrinkage at four months, avoided enucleation (eye removal), and improved vision from 6/120 to 6/5.
Guidance, Outlook, and Risks
Outlook and Trial Design
- Registrational Trial: Targeting initiation of a Phase 2/3 trial in Q2 2023 for first-line HLA-A2 negative MUM patients.
- Design: Integrated Phase 2/3 open-label study-in-study. Phase 2 primary endpoint is median PFS (for potential accelerated approval); Phase 3 will evaluate Overall Survival (OS).
- Enrollment: Phase 2 portion plans to randomize ~230 patients (2:1 treatment vs. control). Phase 3 portion will add ~120 patients.
- Market Opportunity: Estimated addressable population includes ~4,500 annual MUM patients and ~8,700 annual (neo)adjuvant UM patients in the US and Europe.
Risks and Contingencies
- Forward-Looking Statements: Results are preliminary and based on investigator review from an unlocked database.
- Development Risks: Uncertainties in drug development, regulatory approval, manufacturing, and intellectual property.
- External Factors: Impact of the COVID-19 pandemic and the Russia-Ukraine conflict on operations and cash sufficiency.
Investor Verification Checklist
- Verify the timeline for the initiation of the Phase 2/3 registrational trial in Q2 2023.
- Confirm the final independent central review (BICR) data for the Phase 2 expansion cohort once the database is locked.
- Monitor the Company's cash runway and capital raise activities, as this filing does not disclose current liquidity levels.
- Track regulatory feedback from the FDA regarding the Phase 2/3 trial design and potential accelerated approval pathways.
- Review the safety profile in the larger Phase 2/3 cohort to confirm the low rate of serious adverse events observed in the interim data.